ArticleJournal of ovarian research2025
Pembrolizumab plus chemotherapy followed by maintenance with or without olaparib as first-line treatment for advanced BRCAwt ovarian cancer with LOH-low: a international cost-effectiveness analysis.
Article in Journal of ovarian research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Receptor Co‑targeting Strategies for Personalized Ovarian Cancer Therapy.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundPatients with advanced ovarian cancer (AOC) who are BRCA wild-type (BRCAwt) or exhibit low loss of heterozygosity (LOH-low) typically face a poor prognosis and have limited therapeutic options. Pembrolizumab plus chemotherapy followed by maintenance with or without olaparib (PCO or PC) brings new hope to these patients. However, the substantial financial burden associated with these regimens necessitates a thorough cost-effectiveness evaluation.
methodsThe 20-year horizon Markov model with three health states was developed using clinical data from the KEYLYNK-001 trial and associated treatment costs to estimate the lifetime costs and health benefits of PCO, PC, and chemotherapy. Primary outcomes included total costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs). Cost-effectiveness was assessed using willingness-to-pay (WTP) thresholds of $150,000/QALY for the USA and $39,695/QALY for China.
resultsIn the USA, the total costs and QALYs were $934,191 and 4.74 for PC, and $521,690 and 4.02 for chemotherapy. The corresponding ICERs were $568,586/QALY in the general population and $399,919/QALY among those with programmed cell death ligand 1 combined positive scores (PD-L1 CPS) ≥ 10. In China, PC and chemotherapy incurred costs of $126,542 and $106,247, with QALYs of 4.27 and 3.68, respectively. The ICERs were $34,032/QALY overall and $18,462/QALY in the PD-L1 CPS ≥ 10 population. In both countries, PCO yielded higher costs but lower effectiveness compared to PC.
conclusionsIn BRCAwt AOC patients with LOH-low, PC is a cost-effective first-line treatment compared to PCO in both the USA and China, particularly among PD-L1 CPS ≥ 10 population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.